In mid-March 2020 , IFN-alpha and umifenovir were being developed as post-infection antiviral agents , with numerous other candidates in early-stage research.
Drugs such as IFN-alpha and umifenovir were being developed as post-infection antiviral agents to treat COVID-19 in early 2020 .